Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung
复制标题
DOI：
10.1093/jjco/hym053
复制
发表时间：
2007-07-01
影响因子：
2.4
通讯作者：
Tamura, Tomohide
中科院分区：
文献类型：
--
作者：
Fujiwara, Yutaka;Sekine, Ikuo;Tamura, Tomohide
背景：化疗在肺大细胞神经内分泌癌（LCNEC）患者中的疗效尚不清楚。方法：在连续42例LCNEC患者中，22例可测量疾病接受化疗的患者被纳入本研究。回顾性分析这些患者的临床特点和客观化疗反应。结果：男性21例，女性1例（年龄中位数：67岁，范围：47 ~ 78岁），疾病分期分布：1113期（n = 1）、IIIA期（n = 1）、11113期（n = 5）、IV期（n = 8）、术后复发（n = 7）。化疗方案包括顺铂+伊立替康（n = 9），铂+紫杉醇（n = 6），紫杉醇单用（n = 1），顺铂+长春瑞滨（n = 1），顺铂+多西紫杉醇（n = 1），铂+依托泊苷（n = 4）。22例患者的客观有效率为59.1% （95% Cl, 38.1-80.1）。接受伊立替康治疗的9例患者中有5例获得客观反应，接受紫杉醇治疗的7例患者中有5例获得客观反应。无进展生存期、中位总生存期和1年生存率分别为4.1个月（95% Cl, 3.1-5.1）、10.3个月（95% Cl, 5.8-14.8）和43.0% （95% Cl, 20.7-65.3）。接受伊立替康或紫杉醇治疗的患者中位总生存期为10.3个月（95% Cl, 0-21.8）， 1年生存率为47.6% （95% Cl, 20.4-74.8）。结论：伊立替康和紫杉醇可能具有抗LCNEC的活性。
Background: The efficacy of chemotherapy in patients with large cell neuroendocrine carcinoma of the lung (LCNEC) remains unclear.Methods: Of 42 consecutive patients with LCNEC, 22 with measurable disease receiving chemotherapy were enrolled as the subjects of this study. The clinical characteristics and objective responses to chemotherapy in these patients were analysed retrospectively.Results: The distribution of the disease stage in the patients consisting of 21 males and one female (median age: 67 years; range: 47-78 years) was as follows: stage 1113 (n = 1), stage IIIA (n = 1), stage 11113 (n = 5), stage IV (n = 8), and post-operative recurrence (n = 7). Chemotherapy consisted of cisplatin and irinotecan (n = 9), a platinum agent and paclitaxel (n = 6), paclitaxel alone (n = 1), cisplatin and vinorelbine (n = 1), cisplatin and docetaxel (n = 1), and a platinum and etoposide (n = 4). The objective response rate in the 22 patients was 59.1% (95% Cl, 38.1-80.1). An objective response was obtained in five of the nine patients receiving irinotecan and five of the seven patients receiving paclitaxel. The progression-free survival, median overall survival and 1-year survival rates were 4.1 months (95% Cl, 3.1-5.1), 10.3 months (95% Cl, 5.8-14.8) and 43.0% (95% Cl, 20.7-65.3), respectively. The median overall survival of the patients treated with irinotecan or paclitaxel was 10.3 months (95% Cl, 0-21.8), and the 1-year survival rate of these patients was 47.6% (95% Cl, 20.4-74.8).Conclusion: Our results suggest that irinotecan and paclitaxel may be active against LCNEC.